Immuneering published preclinical data in Cancer Research on atebimetinib, highlighting its differentiated Deep Cyclic Inhibition mechanism and broad antitumor

Immuneering published preclinical data in Cancer Research on atebimetinib, highlighting its differentiated Deep Cyclic Inhibition mechanism and broad antitumor activity. The findings add support to the biotech’s expanding oncology pipeline and clinical push.